LEXINGTON, Mass., – September 20, 2004 – Synta Pharmaceuticals Corp., an emerging pharmaceutical company, today announced that Safi Bahcall, Ph.D., President and Chief Executive Officer, will present at the UBS Global Life Sciences Conference. Dr. Bahcall will provide a corporate overview and an update on the Company's clinical pipeline. The presentation will be delivered at 9:30 a.m. EDT on Monday, September 27, 2004 from The Grand Hyatt in New York City.
Audio transmission of the presentation will be webcast live and can be
accessed from the UBS website at www.ibb.ubs.com. A replay of the presentation
will be available until October 30, 2004.
Synta Pharmaceuticals is an emerging pharmaceutical company focused on discovering, developing, and commercializing products for extending and enhancing the lives of patients with severe medical conditions. Synta has a diverse pipeline of first-in-class, small-molecule drug candidates for the treatment of major immune disorders and cancers, with two lead products in multiple Phase 2 clinical trials. All clinical candidates were developed internally, and Synta fully owns all rights in all indications and markets. Synta developed as a buyout of the U.S. subsidiary of a large Japanese pharmaceutical company in 2002 and, as a result, has an experienced and fully-integrated drug discovery and development operation. Synta has raised over $128 million in private financing in the last three years to support its plans. For more information, please see www.syntapharma.com.